Novel agents to target treatment resistance in ovarian cancer

Christina R. Washington; Debra L. Richardson; Amma F. Agyemang; Kunle O. Odunsi; Kathleen N. Moore

doi:10.1016/B978-0-12-819840-7.00008-X

Novel agents to target treatment resistance in ovarian cancer

Christina R. Washington, Debra L. Richardson, Amma F. Agyemang, Kunle O. Odunsi, Kathleen N. Moore

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.

Original language	English (US)
Title of host publication	Overcoming Ovarian Cancer Chemoresistance
Publisher	Elsevier
Pages	129-149
Number of pages	21
ISBN (Electronic)	9780128198407
ISBN (Print)	9780128198414
DOIs	https://doi.org/10.1016/B978-0-12-819840-7.00008-X
State	Published - Jan 1 2020
Externally published	Yes

Keywords

Chemoresistance
Clinical trials
Novel agents
Recurrence
Targeted treatment

ASJC Scopus subject areas

Agricultural and Biological Sciences(all)
Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/B978-0-12-819840-7.00008-X

Cite this

@inbook{c0b7de7475d94c8c9c9b196a36f12be1,

title = "Novel agents to target treatment resistance in ovarian cancer",

abstract = "Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.",

keywords = "Chemoresistance, Clinical trials, Novel agents, Recurrence, Targeted treatment",

author = "Washington, {Christina R.} and Richardson, {Debra L.} and Agyemang, {Amma F.} and Odunsi, {Kunle O.} and Moore, {Kathleen N.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-819840-7.00008-X",

language = "English (US)",

isbn = "9780128198414",

pages = "129--149",

booktitle = "Overcoming Ovarian Cancer Chemoresistance",

publisher = "Elsevier",

}

TY - CHAP

T1 - Novel agents to target treatment resistance in ovarian cancer

AU - Washington, Christina R.

AU - Richardson, Debra L.

AU - Agyemang, Amma F.

AU - Odunsi, Kunle O.

AU - Moore, Kathleen N.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.

AB - Chemotherapy resistance is a common occurrence in women who have undergone treatment for epithelial ovarian cancer. Combination chemotherapy, while helpful in delaying the development of resistance, carries increased toxicity and a poorer safety profile. As a result, numerous studies are investigating additional pharmacological targets, combination therapies, and repurposed agents for ovarian cancer treatment. This chapter summarizes clinical studies investigating novel combination therapies and targeted treatments that may hold promise in future clinical applications.

KW - Chemoresistance

KW - Clinical trials

KW - Novel agents

KW - Recurrence

KW - Targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=85142087198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142087198&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-819840-7.00008-X

DO - 10.1016/B978-0-12-819840-7.00008-X

M3 - Chapter

AN - SCOPUS:85142087198

SN - 9780128198414

SP - 129

EP - 149

BT - Overcoming Ovarian Cancer Chemoresistance

PB - Elsevier

ER -

Novel agents to target treatment resistance in ovarian cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this